Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 31

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 31
---
 protect our proprietary technology and intellectual property, and to operate without
infringing or violating the proprietary rights of others. We rely on a combination of patent, trademark, trade secret and copyright laws,
know-how, intellectual property licenses and other contractual rights (including confidentiality and invention assignment agreements)
to protect our proprietary technology and intellectual property, including related intellectual property rights.

Patents

As
of March 12, 2025, we own 58 granted patents and 11 pending patent applications to use within our field of business. Our patents and
patent applications generally relate to compositions and methods for treating cancer and infectious diseases, and our patents and any
patents that issue from our pending patent applications are expected to expire at various dates between 2033 and 2043.

We
intend to submit patent applications for each new product and technology that we develop. The patent outlook for companies like ours
is generally uncertain and may involve complex legal and factual questions. Our ability to maintain and consolidate our proprietary position
for our technology will depend on our success in obtaining effective claims and enforcing those claims once granted. We do not know whether
any of our patent applications or any patent applications that we may license will result in the issuance of any patents. Our issued
patents and those that may be issued in the future, or patents that we may exclusively license, may be challenged, narrowed, circumvented
or found to be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products or the length
of term of patent protection that we may have for our products. We cannot be certain that we were the first to invent the inventions
claimed in our owned patents or patent applications. In addition, our competitors may independently develop similar technologies or duplicate
any technology developed by us, and the rights granted under any issued patents may not provide us with any meaningful competitive advantages
against these competitors. Furthermore, because of the extensive time required for development, testing and regulatory review of a potential
product, it is possible that, before any of our products can be commercialized, any related patent may expire or remain in force for
only a short period following commercialization, thereby reducing any advantage of the patent.

Trade
Secrets and Confidential Information

In
addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. Trade secrets and know-how
can be difficult to protect. We rely on, among other things, confidentiality and invention assignment agreements to protect our proprietary